Macroscopic Portal Vein Thrombosis in HCC Patients

dc.contributor.authorAkkiz, Hikmet
dc.contributor.authorCarr, Brian I.
dc.contributor.authorKuran, Sedef
dc.contributor.authorKaraogullarindan, Umit
dc.contributor.authorUskudar, Oguz
dc.contributor.authorTokmak, Salih
dc.contributor.authorKilic, Murat
dc.date.accessioned2026-08-12T17:17:36Z
dc.date.issued2018
dc.departmentFırat Üniversitesi
dc.description.abstractMacroscopic portal vein invasion (PVT) by hepatocellular carcinoma (HCC) in the liver is one of the most important negative prognostic factors for HCC patients. The characteristics of a large cohort of such patients were examined. We found that the percent of patients with PVT significantly increased with increasing maximum tumor diameter (MTD), from 13.7% with tumors of MTD <5cm to 56.4% with tumors of MTD >10cm. There were similar numbers of HCC patients with very large tumors with and without PVT. Thus, MTD alone was insufficient to explain the presence of PVT, as were high AFP levels, since less than 50% of high AFP patients had PVT. However, the percent of patients with PVT was also found to significantly increase with increasing blood alpha-fetoprotein (AFP) levels and tumormultifocality. A logistic regressionmodel that included these 3 factors together showed an odds ratio of 17.9 for the combination of MTD >5.0cm plus tumor multifocality plus elevated AFP, compared to low levels of these 3 parameters. The presence or absence of macroscopic PVT may therefore represent different HCC aggressiveness phenotypes, as judged by a significant increase in tumor multifocality and AFP levels in the PVT positive patients. Factors in addition to MTD and AFP must also contribute to PVT development.
dc.description.sponsorshipNIH [CA 82723]
dc.description.sponsorshipThis work is supported in part by NIH Grant CA 82723 (Brian I. Carr)Y
dc.identifier.doi10.1155/2018/3120185
dc.identifier.issn2291-2789
dc.identifier.issn2291-2797
dc.identifier.orcid0009-0007-5052-2279
dc.identifier.orcid0000-0002-2727-5632
dc.identifier.orcid0000-0002-6111-5077
dc.identifier.orcid0000-0003-0796-1456
dc.identifier.orcid0000-0002-8044-0297
dc.identifier.orcid0000-0001-9745-8875
dc.identifier.orcid0000-0001-5302-8953
dc.identifier.pmid30009156
dc.identifier.scopus2-s2.0-85049358746
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1155/2018/3120185
dc.identifier.urihttps://hdl.handle.net/11508/52733
dc.identifier.volume2018
dc.identifier.wosWOS:000436297600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherHindawi Ltd
dc.relation.ispartofCanadian Journal of Gastroenterology and Hepatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectGamma-Carboxy Prothrombin
dc.subjectUnresectable Hepatocellular-Carcinoma
dc.subjectAutologous Growth-Factor
dc.subjectComputed-Tomography
dc.subjectPrognostic-Factors
dc.subjectAlpha-Fetoprotein
dc.subjectVenous Invasion
dc.subjectTumor
dc.subjectSurvival
dc.subjectUltrasound
dc.titleMacroscopic Portal Vein Thrombosis in HCC Patients
dc.typeArticle

Dosyalar